Clinical Study

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1A (Rebif®) In Patients With Relapsing Multiple Sclerosis

Posted Date: Sep 9, 2017

  • Investigator: Joseph Nicolas
  • Co-Investigator: Melissa Kahler
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

This study is being conducted by F. Hoffmann-La Roche Ltd. (Roche) and Genentech Inc, called “Sponsor” later on in this document. We want to confirm whether patients treated with ocrelizumab may experience even fewer clinical relapses (also called clinic

Criteria:

• You Must Be 18 To 55 Years Of Age. • You Must Pass The Screening Medical Examinations And Tests (Including A Pregnancy Test For Females Who Are Able To Become Pregnant During The Study); If You Or Your Female Partner (If You Are Male) Are Able To Becom

Keywords:

Relapsing-Remitting, Opera, Ocrelizumab, Multiple Sclerosis, Null

For More Information:

Alecia Boehl
513-558-0039
alecia.boehl@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.